“You may choose to look the other way, but you can never say again that you did not know.”
— William Wilberforce
As part of an effort to reopen their borders and encourage travelers from outside of Europe, the 27 member states of the European Union (E.U.) began issuing an “E.U. Digital COVID Certificate” (EUDCC) on July 1, 2021 to people who have receive COVID vaccinations to allow freedom of movement within the region. The travel scheme, […]
On Oct. 20, 2021, the Biden administration outlined plans to begin giving COVID-19 vaccinations to children between five and 11 years old. Pending the results of reviews of the plan by the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) over the […]
Pfizer, Inc. reported that the company sold $7.8 billion worth of their COVID-19 biologic BNT162b2 in the second quarter of this year raising the company’s 2021 sales forecast for the two-dose vaccine to $33.5 billion from the previously estimated $26 billion.1 The $7.8 billion from direct sales of the shot is split with its German […]
With 81 percent of Israel’s adult population (and nearly 59 percent of its overall population) fully vaccinated against COVID-19 and the number of reported SARS-CoV-2 infections down to under 20 cases per day, the Israeli government lifted most COVID-19-related restrictions in the country on June 1, 2021. One of the main remaining restrictions was the […]
Last week was a bad one for COVID-19 biologics produced by Moderna, Inc. and Johnson & Johnson, Inc. (J&J). News reports began filtering out about new research from the U.S. Centers for Disease Control and Prevention (CDC), which were published on Apr. 5, 2021 in the journal JAMA and revealed that people who receive Moderna’s […]
On Nov. 9, 2020, Pfizer, Inc. announced that the experimental messenger RNA (mRNA) BNT162b2 vaccine for COVID-19 it developed in partnership with Germany’s BioNTech SE had an efficacy rate of 90 percent, based on the results of human clinical trials on the vaccine.1 2 3 This news was followed up a week later with an […]
We are learning more about a stock sale by Pfizer CEO Albert Bourla on Monday, the same day the company announced its early vaccine trial results. We’ve seen certain circumstances like this before. That’s right… so remember, of course, Pfizer reported that 90 percent efficacy number on its vaccine trial on Monday. Its stock went […]
Story Highlights On Nov. 9, 2020, Pfizer released preliminary Phase 3 clinical trial data indicating that its experimental mRNA COVID-19 vaccine is 90 percent effective, triggering a big surge in stock price. Pfizer CEO Albert Bourla immediately sold 60 percent of his company stock, realizing a gain of $5.6 million in what the company called […]
On Sept. 8, 2020, nine pharmaceutical companies working on COVID-19 vaccines signed a pledge saying they would not submit their experimental vaccines to the U.S. Food and Drug Administration (FDA) unless they were shown to be both safe and efficacious in the Phase 3 human clinical trials.1 2 3 4 5 The pledge, signed by […]
Pfizer, Inc. of New York and BioNTech SE of Mainz, Germany have announced that human clinical trials for an experimental COVID-19 vaccine they have co-developed, known as BNT162, have begun in the United States.1 As part of a global clinical development program, the first human subjects in the U.S. Phase I and Phase clinical II […]